Back to UBS Group AG UBS Group AG

ELTXELTX
13 quarters

Position history for UBS Group AGUBS Group AG's holdings in ELICIO THERAPEUTICS INC

Yes. Ubs holds 40,419 shares of ELTX (Elicio Therapeutics), worth $158,039, as of its Q2 2026 13F filing. It increased the position by 6,650 shares (+19.7%) from Q1 2026. Ubs has held ELTX since Q2 2023, across 13 quarterly 13F filings.

Current Value

$158,039

Current Shares

40,419

Total Value Change

+$151,911

Total Shares Change

+39,774

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
40,419
+19.7%
$158,0390.0%$3.91
18
2026-Q1
Increased
33,769
+5.5%
$360,9910.0%$10.69
25
2025-Q4
Increased
32,016
+356.1%
$254,8470.0%$7.96
25
2025-Q3
Increased
7,019
+16.5%
$76,7870.0%$10.94
17
2025-Q2
Decreased
6,023
-71.6%
$46,4970.0%$7.72
0
2025-Q1
Increased
21,198
+1246x
$130,5790.0%$6.16
24
2024-Q4
Decreased
17
-98.0%
$870.0%$5.10
0
2024-Q3
Increased
848
+4888.2%
$4,2660.0%$5.03
16
2024-Q2
Increased
17
+6.3%
$700.0%$4.11
8
2024-Q1
Unchanged
16
0.0%
$1220.0%$7.60
0
2023-Q4
Unchanged
16
0.0%
$1330.0%$8.34
0
2023-Q3
Decreased
16
-97.5%
$1350.0%$8.45
0
2023-Q2
New
645
-
$6,1280.0%$9.50
24

Other major holders of ELTX: VANGUARD CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, BlackRock, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used